Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Aadi Bioscience, Inc. on June 14, 2023. The filing details the voting results for four proposals submitted to security holders. The record date for the meeting was April 25, 2023.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing reports the following outcomes from the Annual Meeting:
- Quorum: 13,926,204 shares were present, representing approximately 57% of the voting power.
- Director Elections: Three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve) were elected to serve until the 2026 Annual Meeting.
- Say-on-Pay: Stockholders approved the compensation of named executive officers on an advisory basis.
- Voting Frequency: Stockholders voted to hold future Say-on-Pay votes annually. The next frequency vote is required no later than the 2029 Annual Meeting.
- Auditor Ratification: The appointment of BDO USA LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, or contingencies. It strictly documents the procedural results of the stockholder vote.
Important Facts for Investors to Verify
- Verify the specific terms and qualifications of the newly elected Class III directors in the definitive Proxy Statement filed on April 28, 2023.
- Confirm the details of executive compensation referenced in the "Say-on-Pay" vote by reviewing the 2022 Summary Compensation Table in the Proxy Statement.
- Note that the company has committed to annual Say-on-Pay votes based on the June 14, 2023, results.
- Review the upcoming fiscal year audit scope with BDO USA LLP as the newly ratified auditor.